Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


NAD reviews Colotox

This article was originally published in The Tan Sheet

Executive Summary

The National Advertising Division gives Central Coast Nutraceuticals a second chance to participate in the self-regulatory review process for claims about the firm's Colotox dietary supplement. The Council of Better Business Bureaus' division referred the company to FDA and the Federal Trade Commission in February after the firm failed to respond to NAD's query (1"The Tans Sheet" Feb. 16, 2009, p. 19). Following the referral the advertiser contacted NAD, which reopened the case (2"The Tan Sheet" April 13, 2009, p. 15). NAD says June 3 it determined Central Coast supported claims that Colotox's laxative properties "decrease gas and bloating," "reduce water retention" and relieve constipation. The Phoenix-based firm also supported claims that Colotox increased energy and relieved chronic fatigue. It did not sufficiently support weight-loss claims or claims Colotox removes toxic build-up. The firm says it does not agree with NAD's recommendation to discontinue detoxification claims, but will comply

You may also be interested in...

Nutraceuticals International Spurns NAD Review

Nutraceuticals International says it will answer questions FDA and the Federal Trade Commission may have rather than participate in the National Advertising Division's review of advertising claims for its FucoPure supplement ingredient

NAD Refers Central Coast Nutraceuticals’ Colotox Ads To FTC And FDA

The National Advertising Division will refer Central Coast Nutraceuticals' Colotox advertising to the Federal Trade Commission and FDA for review after the firm failed to respond to an inquiry

DJO Thinks Trilliant Is Brilliant, Announces Acquisition

DJO Global will buy Trilliant Surgical to further its ongoing expansion into the US foot and ankle market.





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts